You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Colorectal cancer not MSI-H or MMR-deficient

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma Trial in France (Phase 1 : Regorafenib,

Recruiting
  • Colorectal Cancer Not MSI-H or MMR-deficient
  • +9 more
  • Phase 1 : Regorafenib
  • +4 more
  • Bordeaux, France
  • +6 more
Dec 6, 2021

Colorectal Cancer Trial in Essen (Atezolizumab)

Recruiting
  • Colorectal Cancer
  • Essen, Germany
    Westdeutsches Tumorzentrum
Feb 14, 2022

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

Recruiting
  • Colorectal Cancer
  • +3 more
  • Neoadjuvant therapy with PD-L1 inhibitor
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

Recruiting
  • Colorectal Carcinoma
  • Guangzhou, China
    Sun Yat-sen University
Dec 29, 2022

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Aug 17, 2023

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • HX008
    • Investigator's Choice Chemotherapy
    • Hefei, Anhui, China
    • +9 more
    Dec 8, 2022

    MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

    Not yet recruiting
    • MSI-H Colorectal Cancer
    • +3 more
    • (no location specified)
    Apr 23, 2023

    dMMR Colorectal Cancer Trial in Beijing (Cadonilimab)

    Recruiting
    • dMMR Colorectal Cancer
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Apr 13, 2023

    Adenocarcinoma of the Colon Trial in London (Pembrolizumab)

    Recruiting
    • Adenocarcinoma of the Colon
    • London, United Kingdom
      University College Hospital
    Jul 20, 2022

    Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

    Not yet recruiting
    • Adenocarcinoma - GEJ
    • Gastric Adenocarcinoma
    • (no location specified)
    Sep 26, 2023

    MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

    Not yet recruiting
    • MSI-H
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 26, 2023

    Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

    Not yet recruiting
    • Gastric
    • Colorectal Adenocarcinoma
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital & Institute
    Nov 1, 2023

    DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

    Not yet recruiting
    • Endometrial Cancer
    • (no location specified)
    Feb 14, 2023

    Immunotherapy in MSI-H Metastatic Colorectal Cancer

    Recruiting
    • Colorectal Cancer
    • Carpi, Modena, Italy
      Ospedale Ramazzini
    Sep 5, 2022

    Colorectal Cancer Trial in China (Tislelizumab)

    Recruiting
    • Colorectal Cancer
    • Bengbu, Anhui, China
    • +7 more
    Sep 13, 2022

    Anti-PD-1 Antibody, Radiotherapy, Rectal Cancer Trial in Chengdu (Sintilimab, Hypofractionated Radiotherapy)

    Recruiting
    • Anti-PD-1 Antibody
    • +4 more
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Apr 25, 2022

    Solid Tumor Trial in Beijing (KN035)

    Recruiting
    • Solid Tumor
    • KN035
    • Beijing, Beijing, China
      Peking University Cancer Hospital, Peking University
    Apr 5, 2022

    Endometrial Cancer Trial in United States (Intensity modulated radiation therapy (IMRT), Dostarlimab)

    Recruiting
    • Endometrial Cancer
    • Basking Ridge, New Jersey
    • +6 more
    Jul 5, 2022

    MSI-H Colorectal Cancer Trial (colorectal resection)

    Completed
    • MSI-H Colorectal Cancer
    • colorectal resection
    • (no location specified)
    May 22, 2023